Shareholders might have noticed that Cencora, Inc. (NYSE:COR) filed its quarterly result this time last week. The early response was not positive, with shares down 3.1% to US$283 in the past week.

May 7 (Reuters) - U.S. drug distributor Cencora (COR.N), opens new tab raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Leadership with Impact Ed Bowen ... this distinguished Board and look forward to engaging the Cencora team to help accelerate ...

Cencora (COR) came out with quarterly earnings ... of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry ...

Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a pharmaceutical sourcing and distribution company. With a market cap of approximately $54 billion, Cencora operates through the U.S ...

Analysts raised questions about the impact of tariffs ... logistics and subdued clinical trial activity impacting results. Cencora delivered a strong quarter with notable growth in the U.S ...

Seven African healthtech startups have been selected for the third cohort of the Investing in Innovation Africa (i3) program, ...

Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter ... quarter earnings call last year. Excluding the impact of the manufacturers' price adjustments, we saw solid ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal second-quarter profit of $717.9 million. On a per-share basis, the Conshohocken, Pennsylvania ...